{"protocolSection": {"identificationModule": {"nctId": "NCT00739973", "orgStudyIdInfo": {"id": "CSPA100A2305"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension", "officialTitle": "An 8-week Double-blind, Multicenter, Randomized, Multifactorial, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Amlodipine in Patients With Essential Hypertension"}, "statusModule": {"statusVerifiedDate": "2011-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-09"}, "primaryCompletionDateStruct": {"date": "2009-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-08-20", "studyFirstSubmitQcDate": "2008-08-21", "studyFirstPostDateStruct": {"date": "2008-08-22", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-01-13", "resultsFirstSubmitQcDate": "2011-03-31", "resultsFirstPostDateStruct": {"date": "2011-05-03", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-06-02", "lastUpdatePostDateStruct": {"date": "2011-06-06", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "External Affairs", "oldOrganization": "Novartis Pharmaceuticals"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Evaluate the efficacy (blood pressure lowering effect) and safety of aliskiren alone and in combination with amlodipine in patients with essential hypertension."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Hypertension, Aliskiren, Amlodipine"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "FACTORIAL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 2694, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 5 of the 5 pills taken were placebos.", "interventionNames": ["Drug: Placebo"]}, {"label": "Aliskiren 150 mg tablet", "type": "EXPERIMENTAL", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.", "interventionNames": ["Drug: Placebo", "Drug: Aliskiren 150 mg tablet"]}, {"label": "Aliskiren 300 mg tablet", "type": "EXPERIMENTAL", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.", "interventionNames": ["Drug: Placebo", "Drug: Aliskiren 300 mg tablet"]}, {"label": "Amlodipine 5 mg capsule", "type": "EXPERIMENTAL", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.", "interventionNames": ["Drug: Placebo", "Drug: Amlodipine 5 mg capsule"]}, {"label": "Amlodipine 10 mg capsule", "type": "EXPERIMENTAL", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos. Amlodipine 10 mg arm starts with 1 week of Amlodipine 5 mg, then force titrated to 10 mg", "interventionNames": ["Drug: Placebo", "Drug: Amlodipine 10 mg capsule"]}, {"label": "Aliskiren/amlodipine 150/5 mg tablet", "type": "EXPERIMENTAL", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.", "interventionNames": ["Drug: Placebo", "Drug: Aliskiren/amlodipine 150/5 mg tablet"]}, {"label": "Aliskiren/amlodipine 150/10 mg tablet", "type": "EXPERIMENTAL", "description": "150/5 for 1 week, then up-titrated to 150/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.", "interventionNames": ["Drug: Placebo", "Drug: Aliskiren/amlodipine 150/10 mg tablet"]}, {"label": "Aliskiren/amlodipine 300/5 mg tablet", "type": "EXPERIMENTAL", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.", "interventionNames": ["Drug: Placebo", "Drug: Aliskiren/amlodipine 300/5 mg tablet"]}, {"label": "Aliskiren/amlodipine 300/10 mg tablet", "type": "EXPERIMENTAL", "description": "300/5 for 1 week, then up-titrated to 300/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.", "interventionNames": ["Drug: Placebo", "Drug: Aliskiren/amlodipine 300/10 mg tablet"]}], "interventions": [{"type": "DRUG", "name": "Placebo", "armGroupLabels": ["Aliskiren 150 mg tablet", "Aliskiren 300 mg tablet", "Aliskiren/amlodipine 150/10 mg tablet", "Aliskiren/amlodipine 150/5 mg tablet", "Aliskiren/amlodipine 300/10 mg tablet", "Aliskiren/amlodipine 300/5 mg tablet", "Amlodipine 10 mg capsule", "Amlodipine 5 mg capsule", "Placebo"]}, {"type": "DRUG", "name": "Aliskiren 150 mg tablet", "armGroupLabels": ["Aliskiren 150 mg tablet"]}, {"type": "DRUG", "name": "Aliskiren 300 mg tablet", "armGroupLabels": ["Aliskiren 300 mg tablet"]}, {"type": "DRUG", "name": "Amlodipine 5 mg capsule", "armGroupLabels": ["Amlodipine 5 mg capsule"]}, {"type": "DRUG", "name": "Amlodipine 10 mg capsule", "armGroupLabels": ["Amlodipine 10 mg capsule"]}, {"type": "DRUG", "name": "Aliskiren/amlodipine 150/5 mg tablet", "armGroupLabels": ["Aliskiren/amlodipine 150/5 mg tablet"]}, {"type": "DRUG", "name": "Aliskiren/amlodipine 150/10 mg tablet", "armGroupLabels": ["Aliskiren/amlodipine 150/10 mg tablet"]}, {"type": "DRUG", "name": "Aliskiren/amlodipine 300/5 mg tablet", "armGroupLabels": ["Aliskiren/amlodipine 300/5 mg tablet"]}, {"type": "DRUG", "name": "Aliskiren/amlodipine 300/10 mg tablet", "armGroupLabels": ["Aliskiren/amlodipine 300/10 mg tablet"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Aliskiren 150 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "timeFrame": "Baseline to end of study (Week 8)"}, {"measure": "Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "timeFrame": "Baseline to end of study (Week 8)"}, {"measure": "Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "timeFrame": "Baseline to end of study (Week 8)"}, {"measure": "Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Aliskiren 150 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "timeFrame": "Baseline to end of study (Week 8)"}, {"measure": "Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "timeFrame": "Baseline to end of study (Week 8)"}, {"measure": "Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "timeFrame": "Baseline to end of study (Week 8)"}, {"measure": "Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Aliskiren 300 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "timeFrame": "Baseline to end of study (Week 8)"}, {"measure": "Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "timeFrame": "Baseline to end of study (Week 8)"}, {"measure": "Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "timeFrame": "Baseline to end of study (Week 8)"}, {"measure": "Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Aliskiren 300 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "timeFrame": "Baseline to end of study (Week 8)"}, {"measure": "Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "timeFrame": "Baseline to end of study (Week 8)"}, {"measure": "Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "timeFrame": "Baseline to end of study (Week 8)"}], "secondaryOutcomes": [{"measure": "Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Aliskiren 150 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "timeFrame": "Baseline to end of study (Week 8)"}, {"measure": "Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "timeFrame": "Baseline to end of study (Week 8)"}, {"measure": "Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "timeFrame": "Baseline to end of study (Week 8)"}, {"measure": "Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Aliskiren 150 mg on Change in Mean Sitting Systolic Blood Pressure (mssBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "timeFrame": "Baseline to end of study (Week 8)"}, {"measure": "Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "timeFrame": "Baseline to end of study (Week 8)"}, {"measure": "Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "timeFrame": "Baseline to end of study (Week 8)"}, {"measure": "Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Aliskiren 300 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "timeFrame": "Baseline to end of study (Week 8)"}, {"measure": "Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "timeFrame": "Baseline to end of study (Week 8)"}, {"measure": "Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "timeFrame": "Baseline to end of study (Week 8)"}, {"measure": "Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Aliskiren 300 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "timeFrame": "Baseline to end of study (Week 8)"}, {"measure": "Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "timeFrame": "Baseline to end of study (Week 8)"}, {"measure": "Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "timeFrame": "Baseline to end of study (Week 8)"}, {"measure": "Percentage of Patients With Blood Pressure Control (msSBP < 140 mm Hg and msDBP < 90 mm Hg) at End of Study", "description": "Blood pressure control defined as msSBP \\< 140 mm Hg and msDBP \\< 90 mm Hg. The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "timeFrame": "End of study (Week 8)"}, {"measure": "Percentage of Patients Achieving a Successful Diastolic Blood Pressure Response", "description": "Blood pressure response in msDBP is defined as a mean sitting diastolic blood pressure \\< 90 mmHg or a \\>=10 mmHg reduction from baseline. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "timeFrame": "End of study (Week 8)"}, {"measure": "Percentage of Patients Achieving a Successful Systolic Blood Pressure Response", "description": "Blood pressure response in msSBP is defined as a mean sitting systolic blood pressure \\< 140 mmHg or a \\>= 20 mmHg reduction from baseline. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "timeFrame": "End of study (Week 8)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* msDBP \u2265 90 mmHg and \\< 110 mmHg at the visit prior to Visit 3 (Visit 2 or optional Visit 201)\n* msDBP \u2265 95 mmHg and \\< 110 mmHg at Visit 3 (Day 1 / randomization).\n* All patients must have an absolute difference of \u2264 10 mmHg in their msDBP during the last 2 visits of the single-blind run-in period (Visit 2 and 3 or Visits 201 and 3).\n\nExclusion Criteria:\n\n* Severe hypertension\n* Pregnant or nursing (lactating) women\n* Women of child-bearing potential\n* Previous or current diagnosis of heart failure (NYHA Class II-IV).\n* Serum potassium \u2265 5.3 mEq/L (mmol/L) at Visit 1.\n* Uncontrolled Type 1 or Type 2 diabetes mellitus\n* Hypersensitivity to renin inhibitors, calcium channel blockers, or to drugs with Similar chemical structures\n* History of malignancy within 5 years\n* History of hypertensive encephalopathy or cerebrovascular accident, or history of transient ischemic attack (TIA), myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis", "affiliation": "Novartis", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Investigative Site", "city": "East Hanover", "state": "New Jersey", "country": "United States", "geoPoint": {"lat": 40.8201, "lon": -74.36487}}, {"facility": "Investigative Site", "city": "Buenos Aires", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Invesigative Site", "city": "Canberra", "country": "Australia", "geoPoint": {"lat": -35.28346, "lon": 149.12807}}, {"facility": "Investigative Site", "city": "Toronto", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Investigative Site", "city": "Bogota", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "Investigative Site", "city": "Copenhagen", "country": "Denmark", "geoPoint": {"lat": 55.67594, "lon": 12.56553}}, {"facility": "Investigative Site", "city": "Oslo", "country": "Finland"}, {"facility": "Investigative Site", "city": "Athens", "country": "Greece", "geoPoint": {"lat": 37.97945, "lon": 23.71622}}, {"facility": "Investigative Site", "city": "Rome", "country": "Italy", "geoPoint": {"lat": 41.89193, "lon": 12.51133}}, {"facility": "Investigative Site", "city": "Mexico City", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Investigative Site", "city": "Panama City", "country": "Panama", "geoPoint": {"lat": 8.9936, "lon": -79.51973}}, {"facility": "Investigative Site", "city": "Lima", "country": "Peru", "geoPoint": {"lat": -12.04318, "lon": -77.02824}}, {"facility": "Investigative Site", "city": "Bucharest", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Investigative Site", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Investigative Site", "city": "Pretoria", "country": "South Africa", "geoPoint": {"lat": -25.74486, "lon": 28.18783}}, {"facility": "Investigative Site", "city": "Madrid", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "Investigative Site", "city": "Stockholm", "country": "Sweden", "geoPoint": {"lat": 59.33258, "lon": 18.0649}}, {"facility": "Investigative Site", "city": "Taipei", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "A total of 2694 patients enrolled in the single-blind, placebo run-in period (2 to 4 weeks) of the study. A total of 1688 patients were randomized into the double-blind treatment period (8 weeks). Three patients were mis-randomized, as they were discontinued from the single-blind period and were not treated in the double-blind period.", "groups": [{"id": "FG000", "title": "Placebo", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; for this arm all the 5 pills taken were placebos."}, {"id": "FG001", "title": "Aliskiren 150 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "FG002", "title": "Aliskiren 300 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "FG003", "title": "Amlodipine 5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "FG004", "title": "Amlodipine 10 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos. Amlodipine 10 mg arm starts with 1 week of Amlodipine 5 mg, then force titrated to 10 mg."}, {"id": "FG005", "title": "Aliskiren/Amlodipine 150/5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "FG006", "title": "Aliskiren/Amlodipine 150/10 mg", "description": "150/5 for 1 week, then up-titrated to 150/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "FG007", "title": "Aliskiren/Amlodipine 300/5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "FG008", "title": "Aliskiren/Amlodipine 300/10 mg Tablet", "description": "300/5 for 1 week, then up-titrated to 300/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}], "periods": [{"title": "Single-blind Period (2 to 4 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "In this period, participants were enrolled to only Placebo arm.", "numSubjects": "2694"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1685"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1009"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "35"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}]}, {"type": "Abnormal laboratory value(s)", "reasons": [{"groupId": "FG000", "numSubjects": "38"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}]}, {"type": "Abnormal test procedure result(s)", "reasons": [{"groupId": "FG000", "numSubjects": "810"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}]}, {"type": "Patient withdrew consent", "reasons": [{"groupId": "FG000", "numSubjects": "86"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}]}, {"type": "Administrative problems", "reasons": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}]}, {"type": "Protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}]}]}, {"title": "Double-blind:Randomized Period (8 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "198"}, {"groupId": "FG001", "comment": "One pt. was mis-randomized, so discontinued from single-blind and was untreated in the double-blind.", "numSubjects": "195"}, {"groupId": "FG002", "numSubjects": "203"}, {"groupId": "FG003", "numSubjects": "185"}, {"groupId": "FG004", "numSubjects": "181"}, {"groupId": "FG005", "numSubjects": "181"}, {"groupId": "FG006", "comment": "2 pts. were mis-randomized, so discontinued from single-blind and were untreated in double-blind.", "numSubjects": "183"}, {"groupId": "FG007", "numSubjects": "178"}, {"groupId": "FG008", "numSubjects": "184"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "168"}, {"groupId": "FG001", "numSubjects": "175"}, {"groupId": "FG002", "numSubjects": "184"}, {"groupId": "FG003", "numSubjects": "173"}, {"groupId": "FG004", "numSubjects": "162"}, {"groupId": "FG005", "numSubjects": "169"}, {"groupId": "FG006", "numSubjects": "170"}, {"groupId": "FG007", "numSubjects": "168"}, {"groupId": "FG008", "numSubjects": "170"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "30"}, {"groupId": "FG001", "numSubjects": "20"}, {"groupId": "FG002", "numSubjects": "19"}, {"groupId": "FG003", "numSubjects": "12"}, {"groupId": "FG004", "numSubjects": "19"}, {"groupId": "FG005", "numSubjects": "12"}, {"groupId": "FG006", "numSubjects": "13"}, {"groupId": "FG007", "numSubjects": "10"}, {"groupId": "FG008", "numSubjects": "14"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "7"}, {"groupId": "FG005", "numSubjects": "3"}, {"groupId": "FG006", "numSubjects": "4"}, {"groupId": "FG007", "numSubjects": "1"}, {"groupId": "FG008", "numSubjects": "4"}]}, {"type": "Abnormal laboratory values", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "1"}, {"groupId": "FG008", "numSubjects": "0"}]}, {"type": "Abnormal test procedure results", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}]}, {"type": "Unsatisfactory therapeutic effect", "reasons": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "4"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}, {"groupId": "FG006", "numSubjects": "1"}, {"groupId": "FG007", "numSubjects": "1"}, {"groupId": "FG008", "numSubjects": "2"}]}, {"type": "Patient no longer needs study drug", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}]}, {"type": "Patient withdrew consent", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "4"}, {"groupId": "FG005", "numSubjects": "4"}, {"groupId": "FG006", "numSubjects": "3"}, {"groupId": "FG007", "numSubjects": "2"}, {"groupId": "FG008", "numSubjects": "4"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "3"}, {"groupId": "FG008", "numSubjects": "1"}]}, {"type": "Administrative problems", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "1"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}]}, {"type": "Protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "3"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "2"}, {"groupId": "FG007", "numSubjects": "2"}, {"groupId": "FG008", "numSubjects": "3"}]}, {"type": "Discont. single-blind, Mis- randomized", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "2"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; for this arm all the 5 pills taken were placebos."}, {"id": "BG001", "title": "Aliskiren 150 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "BG002", "title": "Aliskiren 300 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "BG003", "title": "Amlodipine 5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "BG004", "title": "Amlodipine 10 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos. Amlodipine 10 mg arm starts with 1 week of Amlodipine 5 mg, then force titrated to 10 mg."}, {"id": "BG005", "title": "Aliskiren/Amlodipine 150/5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "BG006", "title": "Aliskiren/Amlodipine 150/10 mg", "description": "150/5 for 1 week, then up-titrated to 150/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "BG007", "title": "Aliskiren/Amlodipine 300/5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "BG008", "title": "Aliskiren/Amlodipine 300/10 mg Tablet", "description": "300/5 for 1 week, then up-titrated to 300/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "BG009", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "198"}, {"groupId": "BG001", "value": "195"}, {"groupId": "BG002", "value": "203"}, {"groupId": "BG003", "value": "185"}, {"groupId": "BG004", "value": "181"}, {"groupId": "BG005", "value": "181"}, {"groupId": "BG006", "value": "183"}, {"groupId": "BG007", "value": "178"}, {"groupId": "BG008", "value": "184"}, {"groupId": "BG009", "value": "1688"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "53.7", "spread": "10.32"}, {"groupId": "BG001", "value": "54.3", "spread": "11.07"}, {"groupId": "BG002", "value": "54.0", "spread": "9.99"}, {"groupId": "BG003", "value": "54.2", "spread": "11.61"}, {"groupId": "BG004", "value": "55.0", "spread": "10.34"}, {"groupId": "BG005", "value": "53.9", "spread": "10.82"}, {"groupId": "BG006", "value": "53.0", "spread": "10.59"}, {"groupId": "BG007", "value": "54.8", "spread": "10.29"}, {"groupId": "BG008", "value": "54.4", "spread": "10.86"}, {"groupId": "BG009", "value": "54.1", "spread": "10.65"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "108"}, {"groupId": "BG001", "value": "76"}, {"groupId": "BG002", "value": "108"}, {"groupId": "BG003", "value": "86"}, {"groupId": "BG004", "value": "94"}, {"groupId": "BG005", "value": "84"}, {"groupId": "BG006", "value": "96"}, {"groupId": "BG007", "value": "100"}, {"groupId": "BG008", "value": "78"}, {"groupId": "BG009", "value": "830"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "90"}, {"groupId": "BG001", "value": "119"}, {"groupId": "BG002", "value": "95"}, {"groupId": "BG003", "value": "99"}, {"groupId": "BG004", "value": "87"}, {"groupId": "BG005", "value": "97"}, {"groupId": "BG006", "value": "87"}, {"groupId": "BG007", "value": "78"}, {"groupId": "BG008", "value": "106"}, {"groupId": "BG009", "value": "858"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "SECONDARY", "title": "Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Aliskiren 150 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "populationDescription": "Full Analysis Set (FAS): All participants who were randomized. Participants mis-randomized were excluded from the FAS. Mis-randomized participants refer to participants who were not qualified for randomization but were inadvertently randomized into the study. These participants did not receive study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Aliskiren 150 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "OG001", "title": "Aliskiren/Amlodipine 150/5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "193"}, {"groupId": "OG001", "value": "179"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.67", "spread": "1.01"}, {"groupId": "OG001", "value": "-20.64", "spread": "1.05"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.", "paramType": "Least Square Mean Difference", "paramValue": "-9.97", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-12.81", "ciUpperLimit": "-7.12", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.45"}]}, {"type": "SECONDARY", "title": "Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "populationDescription": "Full Analysis Set (FAS): All participants who were randomized. Participants mis-randomized were excluded from the FAS. Mis-randomized participants refer to participants who were not qualified for randomization but were inadvertently randomized into the study. These participants did not receive study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Amlodipine 5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "OG001", "title": "Aliskiren/Amlodipine 150/5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "184"}, {"groupId": "OG001", "value": "179"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-15.82", "spread": "1.04"}, {"groupId": "OG001", "value": "-20.64", "spread": "1.05"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.", "paramType": "Least Square mean Difference", "paramValue": "-4.82", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.70", "ciUpperLimit": "-1.94", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.47"}]}, {"type": "SECONDARY", "title": "Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "populationDescription": "Full Analysis Set (FAS): All participants who were randomized. Participants mis-randomized were excluded from the FAS. Mis-randomized participants refer to participants who were not qualified for randomization but were inadvertently randomized into the study. These participants did not receive study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; for this arm all the 5 pills taken were placebos."}, {"id": "OG001", "title": "Aliskiren/Amlodipine 150/5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "198"}, {"groupId": "OG001", "value": "179"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-6.79", "spread": "1.00"}, {"groupId": "OG001", "value": "-20.64", "spread": "1.05"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.", "paramType": "Least Square Mean Difference", "paramValue": "-13.85", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-16.68", "ciUpperLimit": "-11.0", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.44"}]}, {"type": "SECONDARY", "title": "Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Aliskiren 150 mg on Change in Mean Sitting Systolic Blood Pressure (mssBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "populationDescription": "Full Analysis Set (FAS): All participants who were randomized. Participants mis-randomized were excluded from the FAS. Mis-randomized participants refer to participants who were not qualified for randomization but were inadvertently randomized into the study. These participants did not receive study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Aliskiren 150 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "OG001", "title": "Aliskiren/Amlodipine 150/10 mg", "description": "150/5 for 1 week, then up-titrated to 150/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "193"}, {"groupId": "OG001", "value": "179"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.67", "spread": "1.01"}, {"groupId": "OG001", "value": "-23.87", "spread": "1.05"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.", "paramType": "Least Square Mean Difference", "paramValue": "-13.20", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-16.04", "ciUpperLimit": "-10.4", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.45"}]}, {"type": "PRIMARY", "title": "Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Aliskiren 150 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "populationDescription": "Full Analysis Set (FAS): All participants who were randomized. Participants mis-randomized were excluded from the FAS. Mis-randomized participants refer to participants who were not qualified for randomization but were inadvertently randomized into the study. These participants did not receive study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Aliskiren 150 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "OG001", "title": "Aliskiren/Amlodipine 150/5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "193"}, {"groupId": "OG001", "value": "179"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-7.99", "spread": "0.63"}, {"groupId": "OG001", "value": "-13.98", "spread": "0.66"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.", "paramType": "Least Square Mean Difference", "paramValue": "-6.00", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.77", "ciUpperLimit": "-4.22", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.90"}]}, {"type": "PRIMARY", "title": "Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "populationDescription": "Full Analysis Set (FAS): All participants who were randomized. Participants mis-randomized were excluded from the FAS. Mis-randomized participants refer to participants who were not qualified for randomization but were inadvertently randomized into the study. These participants did not receive study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Amlodipine 5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "OG001", "title": "Aliskiren/Amlodipine 150/5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "184"}, {"groupId": "OG001", "value": "179"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-11.0", "spread": "0.65"}, {"groupId": "OG001", "value": "-13.98", "spread": "0.66"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.", "paramType": "Least Square Mean Difference", "paramValue": "-2.98", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.77", "ciUpperLimit": "-1.19", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.91"}]}, {"type": "PRIMARY", "title": "Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "populationDescription": "Full Analysis Set (FAS): All participants who were randomized. Participants mis-randomized were excluded from the FAS. Mis-randomized participants refer to participants who were not qualified for randomization but were inadvertently randomized into the study. These participants did not receive study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; for this arm all the 5 pills taken were placebos."}, {"id": "OG001", "title": "Aliskiren/Amlodipine 150/5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "198"}, {"groupId": "OG001", "value": "179"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.35", "spread": "0.62"}, {"groupId": "OG001", "value": "-13.98", "spread": "0.66"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.", "paramType": "Least Square Mean Difference", "paramValue": "-8.63", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.39", "ciUpperLimit": "-6.87", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.90"}]}, {"type": "PRIMARY", "title": "Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Aliskiren 150 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "populationDescription": "Full Analysis Set (FAS): All participants who were randomized. Participants mis-randomized were excluded from the FAS. Mis-randomized participants refer to participants who were not qualified for randomization but were inadvertently randomized into the study. These participants did not receive study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Aliskiren 150 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "OG001", "title": "Aliskiren/Amlodipine 150/10 mg", "description": "150/5 for 1 week, then up-titrated to 150/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "193"}, {"groupId": "OG001", "value": "179"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-7.99", "spread": "0.63"}, {"groupId": "OG001", "value": "-16.16", "spread": "0.66"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.", "paramType": "Least Square Mean Difference", "paramValue": "-8.17", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-9.94", "ciUpperLimit": "-6.40", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.90"}]}, {"type": "PRIMARY", "title": "Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "populationDescription": "Full Analysis Set (FAS): All participants who were randomized. Participants mis-randomized were excluded from the FAS. Mis-randomized participants refer to participants who were not qualified for randomization but were inadvertently randomized into the study. These participants did not receive study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Amlodipine 10 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos. Amlodipine 10 mg arm starts with 1 week of Amlodipine 5 mg, then force titrated to 10 mg."}, {"id": "OG001", "title": "Aliskiren/Amlodipine 150/10 mg", "description": "150/5 for 1 week, then up-titrated to 150/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "179"}, {"groupId": "OG001", "value": "179"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-13.82", "spread": "0.66"}, {"groupId": "OG001", "value": "-16.16", "spread": "0.66"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.011", "statisticalMethod": "ANCOVA", "statisticalComment": "A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.", "paramType": "Least Sqaure Mean Difference", "paramValue": "-2.33", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.14", "ciUpperLimit": "-0.53", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.92"}]}, {"type": "PRIMARY", "title": "Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "populationDescription": "Full Analysis Set (FAS): All participants who were randomized. Participants mis-randomized were excluded from the FAS. Mis-randomized participants refer to participants who were not qualified for randomization but were inadvertently randomized into the study. These participants did not receive study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; for this arm all the 5 pills taken were placebos."}, {"id": "OG001", "title": "Aliskiren/Amlodipine 150/10 mg", "description": "150/5 for 1 week, then up-titrated to 150/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "198"}, {"groupId": "OG001", "value": "179"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.35", "spread": "0.62"}, {"groupId": "OG001", "value": "-16.16", "spread": "0.66"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.", "paramType": "Least Square Mean Difference", "paramValue": "-10.81", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-12.57", "ciUpperLimit": "-9.05", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.90"}]}, {"type": "PRIMARY", "title": "Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Aliskiren 300 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "populationDescription": "Full Analysis Set (FAS): All participants who were randomized. Participants mis-randomized were excluded from the FAS. Mis-randomized participants refer to participants who were not qualified for randomization but were inadvertently randomized into the study. These participants did not receive study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Aliskiren 300 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "OG001", "title": "Aliskiren/Amlodipine 300/5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}, {"groupId": "OG001", "value": "175"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.19", "spread": "0.62"}, {"groupId": "OG001", "value": "-14.99", "spread": "0.66"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.", "paramType": "Least Square Mean Difference", "paramValue": "-4.79", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.56", "ciUpperLimit": "-3.03", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.90"}]}, {"type": "PRIMARY", "title": "Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "populationDescription": "Full Analysis Set (FAS): All participants who were randomized. Participants mis-randomized were excluded from the FAS. Mis-randomized participants refer to participants who were not qualified for randomization but were inadvertently randomized into the study. These participants did not receive study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Amlodipine 5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "OG001", "title": "Aliskiren/Amlodipine 300/5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "184"}, {"groupId": "OG001", "value": "175"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-11.0", "spread": "0.65"}, {"groupId": "OG001", "value": "-14.99", "spread": "0.66"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.", "paramType": "Least Square Mean Difference", "paramValue": "-3.98", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.78", "ciUpperLimit": "-2.18", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.92"}]}, {"type": "PRIMARY", "title": "Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "populationDescription": "Full Analysis Set (FAS): All participants who were randomized. Participants mis-randomized were excluded from the FAS. Mis-randomized participants refer to participants who were not qualified for randomization but were inadvertently randomized into the study. These participants did not receive study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; for this arm all the 5 pills taken were placebos."}, {"id": "OG001", "title": "Aliskiren/Amlodipine 300/5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "198"}, {"groupId": "OG001", "value": "175"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.35", "spread": "0.62"}, {"groupId": "OG001", "value": "-14.99", "spread": "0.66"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.", "paramType": "Least Square Mean Difference", "paramValue": "-9.64", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-11.41", "ciUpperLimit": "-7.87", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.90"}]}, {"type": "PRIMARY", "title": "Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Aliskiren 300 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "populationDescription": "Full Analysis Set (FAS): All participants who were randomized. Participants mis-randomized were excluded from the FAS. Mis-randomized participants refer to participants who were not qualified for randomization but were inadvertently randomized into the study. These participants did not receive study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Aliskiren 300 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "OG001", "title": "Aliskiren/Amlodipine 300/10 mg Tablet", "description": "300/5 for 1 week, then up-titrated to 300/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}, {"groupId": "OG001", "value": "183"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.19", "spread": "0.62"}, {"groupId": "OG001", "value": "-16.45", "spread": "0.65"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.", "paramType": "Least Square Mean Difference", "paramValue": "-6.26", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.00", "ciUpperLimit": "-4.51", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.89"}]}, {"type": "PRIMARY", "title": "Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "populationDescription": "Full Analysis Set (FAS): All participants who were randomized. Participants mis-randomized were excluded from the FAS. Mis-randomized participants refer to participants who were not qualified for randomization but were inadvertently randomized into the study. These participants did not receive study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Amlodipine 10 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos. Amlodipine 10 mg arm starts with 1 week of Amlodipine 5 mg, then force titrated to 10 mg."}, {"id": "OG001", "title": "Aliskiren/Amlodipine 300/10 mg Tablet", "description": "300/5 for 1 week, then up-titrated to 300/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "179"}, {"groupId": "OG001", "value": "183"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-13.82", "spread": "0.66"}, {"groupId": "OG001", "value": "-16.45", "spread": "0.65"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.004", "statisticalMethod": "ANCOVA", "statisticalComment": "A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.", "paramType": "Least Square Mean Difference", "paramValue": "-2.63", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.42", "ciUpperLimit": "-0.83", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.92"}]}, {"type": "PRIMARY", "title": "Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "populationDescription": "Full Analysis Set (FAS): All participants who were randomized. Participants mis-randomized were excluded from the FAS. Mis-randomized participants refer to participants who were not qualified for randomization but were inadvertently randomized into the study. These participants did not receive study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; for this arm all the 5 pills taken were placebos."}, {"id": "OG001", "title": "Aliskiren/Amlodipine 300/10 mg Tablet", "description": "300/5 for 1 week, then up-titrated to 300/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "198"}, {"groupId": "OG001", "value": "183"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.35", "spread": "0.62"}, {"groupId": "OG001", "value": "-16.45", "spread": "0.65"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.", "paramType": "Least Square Mean Difference", "paramValue": "-11.10", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-12.85", "ciUpperLimit": "-9.35", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.89"}]}, {"type": "SECONDARY", "title": "Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "populationDescription": "Full Analysis Set (FAS): All randomized patients who received the study medication.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Amlodipine 10 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos. Amlodipine 10 mg arm starts with 1 week of Amlodipine 5 mg, then force titrated to 10 mg."}, {"id": "OG001", "title": "Aliskiren/Amlodipine 150/10 mg", "description": "150/5 for 1 week, then up-titrated to 150/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "179"}, {"groupId": "OG001", "value": "179"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-21.04", "spread": "1.05"}, {"groupId": "OG001", "value": "-23.87", "spread": "1.05"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.056", "statisticalMethod": "ANCOVA", "statisticalComment": "A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.", "paramType": "Least Square Mean Difference", "paramValue": "-2.83", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.73", "ciUpperLimit": "-0.07", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.48"}]}, {"type": "SECONDARY", "title": "Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "populationDescription": "Full Analysis Set (FAS): All participants who were randomized. Participants mis-randomized were excluded from the FAS. Mis-randomized participants refer to participants who were not qualified for randomization but were inadvertently randomized into the study. These participants did not receive study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; for this arm all the 5 pills taken were placebos."}, {"id": "OG001", "title": "Aliskiren/Amlodipine 150/10 mg", "description": "150/5 for 1 week, then up-titrated to 150/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "198"}, {"groupId": "OG001", "value": "179"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-6.79", "spread": "1.00"}, {"groupId": "OG001", "value": "-23.87", "spread": "1.05"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.", "paramType": "Least Square Mean Difference", "paramValue": "-17.08", "ciPctValue": "95", "ciLowerLimit": "-19.91", "ciUpperLimit": "-14.3", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.44"}]}, {"type": "SECONDARY", "title": "Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Aliskiren 300 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "populationDescription": "Full Analysis Set (FAS): All participants who were randomized. Participants mis-randomized were excluded from the FAS. Mis-randomized participants refer to participants who were not qualified for randomization but were inadvertently randomized into the study. These participants did not receive study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Aliskiren 300 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "OG001", "title": "Aliskiren/Amlodipine 300/5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}, {"groupId": "OG001", "value": "175"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-15.37", "spread": "0.99"}, {"groupId": "OG001", "value": "-21.82", "spread": "1.06"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.", "paramType": "Least Square Mean Difference", "paramValue": "-6.45", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-9.29", "ciUpperLimit": "-3.62", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.45"}]}, {"type": "SECONDARY", "title": "Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "populationDescription": "Full Analysis Set (FAS): All participants who were randomized. Participants mis-randomized were excluded from the FAS. Mis-randomized participants refer to participants who were not qualified for randomization but were inadvertently randomized into the study. These participants did not receive study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Amlodipine 5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "OG001", "title": "Aliskiren/Amlodipine 300/5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "184"}, {"groupId": "OG001", "value": "175"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-15.82", "spread": "1.04"}, {"groupId": "OG001", "value": "-21.82", "spread": "1.06"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "A two-way analysis of covariance model with treatment and region asntwo factors, and the baseline as a covariate.", "paramType": "Least Square Mean Difference", "paramValue": "-6.00", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.90", "ciUpperLimit": "-3.11", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.48"}]}, {"type": "SECONDARY", "title": "Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "populationDescription": "Full Analysis Set (FAS): All participants who were randomized. Participants mis-randomized were excluded from the FAS. Mis-randomized participants refer to participants who were not qualified for randomization but were inadvertently randomized into the study. These participants did not receive study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; for this arm all the 5 pills taken were placebos."}, {"id": "OG001", "title": "Aliskiren/Amlodipine 300/5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "198"}, {"groupId": "OG001", "value": "175"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-6.79", "spread": "1.00"}, {"groupId": "OG001", "value": "-21.82", "spread": "1.06"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Least Square Mean Difference", "paramValue": "-15.03", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-17.88", "ciUpperLimit": "-12.2", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.45"}]}, {"type": "SECONDARY", "title": "Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Aliskiren 300 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "populationDescription": "Full Analysis Set (FAS): All participants who were randomized. Participants mis-randomized were excluded from the FAS. Mis-randomized participants refer to participants who were not qualified for randomization but were inadvertently randomized into the study. These participants did not receive study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Aliskiren 300 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "OG001", "title": "Aliskiren/Amlodipine 300/10 mg Tablet", "description": "300/5 for 1 week, then up-titrated to 300/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}, {"groupId": "OG001", "value": "183"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-15.37", "spread": "0.99"}, {"groupId": "OG001", "value": "-23.19", "spread": "1.04"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.", "paramType": "Least Square Mean Difference", "paramValue": "-7.82", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.63", "ciUpperLimit": "-5.02", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.43"}]}, {"type": "SECONDARY", "title": "Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "populationDescription": "Full Analysis Set (FAS): All participants who were randomized. Participants mis-randomized were excluded from the FAS. Mis-randomized participants refer to participants who were not qualified for randomization but were inadvertently randomized into the study. These participants did not receive study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Amlodipine 10 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos. Amlodipine 10 mg arm starts with 1 week of Amlodipine 5 mg, then force titrated to 10 mg."}, {"id": "OG001", "title": "Aliskiren/Amlodipine 300/10 mg Tablet", "description": "300/5 for 1 week, then up-titrated to 300/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "179"}, {"groupId": "OG001", "value": "183"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-21.04", "spread": "1.05"}, {"groupId": "OG001", "value": "-23.19", "spread": "1.04"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.143", "statisticalMethod": "ANCOVA", "statisticalComment": "A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.", "paramType": "Least Square Mean Difference", "paramValue": "-2.16", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.04", "ciUpperLimit": "0.73", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.47"}]}, {"type": "SECONDARY", "title": "Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "populationDescription": "Full Analysis Set (FAS): All participants who were randomized. Participants mis-randomized were excluded from the FAS. Mis-randomized participants refer to participants who were not qualified for randomization but were inadvertently randomized into the study. These participants did not receive study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; for this arm all the 5 pills taken were placebos."}, {"id": "OG001", "title": "Aliskiren/Amlodipine 300/10 mg Tablet", "description": "300/5 for 1 week, then up-titrated to 300/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "198"}, {"groupId": "OG001", "value": "183"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-6.79", "spread": "1.00"}, {"groupId": "OG001", "value": "-23.19", "spread": "1.04"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.", "paramType": "Least Square Mean Difference", "paramValue": "-16.40", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-19.21", "ciUpperLimit": "-13.6", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.43"}]}, {"type": "SECONDARY", "title": "Percentage of Patients With Blood Pressure Control (msSBP < 140 mm Hg and msDBP < 90 mm Hg) at End of Study", "description": "Blood pressure control defined as msSBP \\< 140 mm Hg and msDBP \\< 90 mm Hg. The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "populationDescription": "All patients who were randomized. Following the intent-to-treat principle, patients will be analyzed according to the treatment they were assigned to at randomization. Patients with baseline and Endpoint msDBP values were included in this analysis.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-05", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "End of study (Week 8)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; for this arm all the 5 pills taken were placebos."}, {"id": "OG001", "title": "Aliskiren 150 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "OG002", "title": "Aliskiren 300 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "OG003", "title": "Amlodipine 5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "OG004", "title": "Amlodipine 10 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos. Amlodipine 10 mg arm starts with 1 week of Amlodipine 5 mg, then force titrated to 10 mg."}, {"id": "OG005", "title": "Aliskiren/Amlodipine 150/5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "OG006", "title": "Aliskiren/Amlodipine 150/10 mg", "description": "150/5 for 1 week, then up-titrated to 150/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "OG007", "title": "Aliskiren/Amlodipine 300/5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "OG008", "title": "Aliskiren/Amlodipine 300/10 mg Tablet", "description": "300/5 for 1 week, then up-titrated to 300/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "198"}, {"groupId": "OG001", "value": "193"}, {"groupId": "OG002", "value": "201"}, {"groupId": "OG003", "value": "184"}, {"groupId": "OG004", "value": "179"}, {"groupId": "OG005", "value": "179"}, {"groupId": "OG006", "value": "179"}, {"groupId": "OG007", "value": "175"}, {"groupId": "OG008", "value": "183"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "19.2"}, {"groupId": "OG001", "value": "26.9"}, {"groupId": "OG002", "value": "36.3"}, {"groupId": "OG003", "value": "35.9"}, {"groupId": "OG004", "value": "50.3"}, {"groupId": "OG005", "value": "49.2"}, {"groupId": "OG006", "value": "65.4"}, {"groupId": "OG007", "value": "56.5"}, {"groupId": "OG008", "value": "68.3"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Achieving a Successful Diastolic Blood Pressure Response", "description": "Blood pressure response in msDBP is defined as a mean sitting diastolic blood pressure \\< 90 mmHg or a \\>=10 mmHg reduction from baseline. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "populationDescription": "All patients who were randomized. Following the intent-to-treat principle, patients will be analyzed according to the treatment they were assigned to at randomization. Patients with baseline and Endpoint msDBP values were included in this analysis.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-05", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "End of study (Week 8)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; for this arm all the 5 pills taken were placebos."}, {"id": "OG001", "title": "Aliskiren 150 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "OG002", "title": "Aliskiren 300 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "OG003", "title": "Amlodipine 5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "OG004", "title": "Amlodipine 10 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos. Amlodipine 10 mg arm starts with 1 week of Amlodipine 5 mg, then force titrated to 10 mg."}, {"id": "OG005", "title": "Aliskiren/Amlodipine 150/5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "OG006", "title": "Aliskiren/Amlodipine 150/10 mg", "description": "150/5 for 1 week, then up-titrated to 150/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "OG007", "title": "Aliskiren/Amlodipine 300/5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "OG008", "title": "Aliskiren/Amlodipine 300/10 mg Tablet", "description": "300/5 for 1 week, then up-titrated to 300/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "198"}, {"groupId": "OG001", "value": "193"}, {"groupId": "OG002", "value": "201"}, {"groupId": "OG003", "value": "184"}, {"groupId": "OG004", "value": "179"}, {"groupId": "OG005", "value": "179"}, {"groupId": "OG006", "value": "179"}, {"groupId": "OG007", "value": "175"}, {"groupId": "OG008", "value": "183"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "34.3"}, {"groupId": "OG001", "value": "50.3"}, {"groupId": "OG002", "value": "54.2"}, {"groupId": "OG003", "value": "62.0"}, {"groupId": "OG004", "value": "74.3"}, {"groupId": "OG005", "value": "73.2"}, {"groupId": "OG006", "value": "83.8"}, {"groupId": "OG007", "value": "73.7"}, {"groupId": "OG008", "value": "84.7"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Achieving a Successful Systolic Blood Pressure Response", "description": "Blood pressure response in msSBP is defined as a mean sitting systolic blood pressure \\< 140 mmHg or a \\>= 20 mmHg reduction from baseline. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.", "populationDescription": "All patients who were randomized. Following the intent-to-treat principle, patients will be analyzed according to the treatment they were assigned to at randomization. Patients with baseline and Endpoint msDBP values were included in this analysis.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-05", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "End of study (Week 8)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; for this arm all the 5 pills taken were placebos."}, {"id": "OG001", "title": "Aliskiren 150 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "OG002", "title": "Aliskiren 300 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "OG003", "title": "Amlodipine 5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "OG004", "title": "Amlodipine 10 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos. Amlodipine 10 mg arm starts with 1 week of Amlodipine 5 mg, then force titrated to 10 mg."}, {"id": "OG005", "title": "Aliskiren/Amlodipine 150/5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "OG006", "title": "Aliskiren/Amlodipine 150/10 mg", "description": "150/5 for 1 week, then up-titrated to 150/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "OG007", "title": "Aliskiren/Amlodipine 300/5 mg", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}, {"id": "OG008", "title": "Aliskiren/Amlodipine 300/10 mg Tablet", "description": "300/5 for 1 week, then up-titrated to 300/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "198"}, {"groupId": "OG001", "value": "193"}, {"groupId": "OG002", "value": "201"}, {"groupId": "OG003", "value": "184"}, {"groupId": "OG004", "value": "179"}, {"groupId": "OG005", "value": "179"}, {"groupId": "OG006", "value": "179"}, {"groupId": "OG007", "value": "175"}, {"groupId": "OG008", "value": "183"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "32.3"}, {"groupId": "OG001", "value": "41.5"}, {"groupId": "OG002", "value": "53.2"}, {"groupId": "OG003", "value": "54.9"}, {"groupId": "OG004", "value": "72.1"}, {"groupId": "OG005", "value": "67.6"}, {"groupId": "OG006", "value": "77.1"}, {"groupId": "OG007", "value": "69.7"}, {"groupId": "OG008", "value": "80.3"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Baseline to end of study (Week 8)", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; for this arm all the 5 pills taken were placebos.", "seriousNumAffected": 2, "seriousNumAtRisk": 198, "otherNumAffected": 22, "otherNumAtRisk": 198}, {"id": "EG001", "title": "Aliskiren 150 mg Tablet", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.", "seriousNumAffected": 0, "seriousNumAtRisk": 194, "otherNumAffected": 15, "otherNumAtRisk": 194}, {"id": "EG002", "title": "Aliskiren 300 mg Tablet", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.", "seriousNumAffected": 0, "seriousNumAtRisk": 203, "otherNumAffected": 18, "otherNumAtRisk": 203}, {"id": "EG003", "title": "Amlodipine 5 mg Capsule", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.", "seriousNumAffected": 1, "seriousNumAtRisk": 185, "otherNumAffected": 18, "otherNumAtRisk": 185}, {"id": "EG004", "title": "Amlodipine 10 mg Capsule", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos. Amlodipine 10 mg arm starts with 1 week of Amlodipine 5 mg, then force titrated to 10 mg.", "seriousNumAffected": 1, "seriousNumAtRisk": 181, "otherNumAffected": 32, "otherNumAtRisk": 181}, {"id": "EG005", "title": "Aliskiren/Amlodipine 150/5 mg Tablet", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.", "seriousNumAffected": 1, "seriousNumAtRisk": 181, "otherNumAffected": 15, "otherNumAtRisk": 181}, {"id": "EG006", "title": "Aliskiren/Amlodipine 150/10 mg Tablet", "description": "150/5 for 1 week, then up-titrated to 150/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.", "seriousNumAffected": 2, "seriousNumAtRisk": 181, "otherNumAffected": 19, "otherNumAtRisk": 181}, {"id": "EG007", "title": "Aliskiren/Amlodipine 300/5 mg Tablet", "description": "Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.", "seriousNumAffected": 1, "seriousNumAtRisk": 178, "otherNumAffected": 8, "otherNumAtRisk": 178}, {"id": "EG008", "title": "Aliskiren/Amlodipine 300/10 mg Tablet", "description": "300/5 for 1 week, then up-titrated to 300/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.", "seriousNumAffected": 1, "seriousNumAtRisk": 184, "otherNumAffected": 30, "otherNumAtRisk": 184}], "seriousEvents": [{"term": "Retinal detachment", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 198}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 194}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 203}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 185}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 181}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 181}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 181}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 178}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 184}]}, {"term": "Abdominal mass", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 198}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 194}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 203}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 185}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 181}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 181}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 181}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 178}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 184}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 198}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 194}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 203}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 185}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 181}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 181}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 181}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 178}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 184}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 198}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 194}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 203}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 185}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 181}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 181}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 181}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 178}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 184}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 198}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 194}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 203}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 185}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 181}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 181}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 181}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 178}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 184}]}, {"term": "Hand fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 198}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 194}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 203}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 185}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 181}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 181}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 181}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 178}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 184}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 198}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 194}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 203}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 185}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 181}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 181}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 181}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 178}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 184}]}, {"term": "Calculus ureteric", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 198}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 194}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 203}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 185}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 181}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 181}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 181}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 178}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 184}]}, {"term": "Hydronephrosis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 198}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 194}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 203}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 185}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 181}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 181}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 181}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 178}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 184}]}], "otherEvents": [{"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 198}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 194}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 203}, {"groupId": "EG003", "numAffected": 8, "numAtRisk": 185}, {"groupId": "EG004", "numAffected": 25, "numAtRisk": 181}, {"groupId": "EG005", "numAffected": 4, "numAtRisk": 181}, {"groupId": "EG006", "numAffected": 14, "numAtRisk": 181}, {"groupId": "EG007", "numAffected": 2, "numAtRisk": 178}, {"groupId": "EG008", "numAffected": 25, "numAtRisk": 184}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 20, "numAtRisk": 198}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 194}, {"groupId": "EG002", "numAffected": 15, "numAtRisk": 203}, {"groupId": "EG003", "numAffected": 11, "numAtRisk": 185}, {"groupId": "EG004", "numAffected": 8, "numAtRisk": 181}, {"groupId": "EG005", "numAffected": 11, "numAtRisk": 181}, {"groupId": "EG006", "numAffected": 8, "numAtRisk": 181}, {"groupId": "EG007", "numAffected": 6, "numAtRisk": 178}, {"groupId": "EG008", "numAffected": 5, "numAtRisk": 184}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862 778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01", "removedCountries": ["Dominican Republic"]}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000075222", "term": "Essential Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "asFound": "Essential Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "C000446481", "term": "Aliskiren"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000092502", "term": "Renin Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M352589", "name": "Aliskiren", "asFound": "Distribution", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M2932", "name": "Renin Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}